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E D I T O R I A L
Increased risk donors: A bird in the hand
Unexpected	donor-	derived	infections	(DDI)	are	relatively	uncommon	
events complicating less than 1% of solid organ transplants.1	Disease	





authorities	 involves	 the	 risk	of	 transmission	of	blood-	borne	viruses:	
human	 immunodeficiency	 virus	 (HIV),	 hepatitis	 B	 virus	 (HBV),	 and	
hepatitis	C	virus	 (HCV).	 In	 2013	 the	Public	Health	 Service	 updated	
a	 set	 of	 behavioral	 criteria	 intended	 to	 identify	 a	 group	 of	 poten-
tial	 donors	 at	 increased	 risk	 for	 recent	HIV,	HCV,	or	HBV	 infection.	
These	donors	may	be	in	the	“window	period”:	infected	with	transmis-
sible	virus	but	 screening	 tests	not	yet	positive.	According	 to	United	
Network	for	Organ	Sharing	(UNOS)	policy,	informed	consent	must	be	
obtained	 from	 recipients	 offered	 organs	 from	 increased-	risk	 donors	
(IRD).	Among	 IRDs,	 the	circumstance	of	greatest	concern	 is	window	
period	 HCV	 infection	 in	 donors	 with	 active	 intravenous	 drug	 use.	
Both	mathematical	modeling	and	limited	data	from	the	UNOS	Disease	
Transmission	Advisory	 Committee	 required	 a	 passive	 reporting	 sys-
tem,	suggesting	that	the	risk	of	window	period	HCV	associated	with	







Three	 major	 changes	 have	 occurred	 over	 the	 past	 decade	 that	
should	make	 us	 reassess	 the	 reasoning	 behind	 the	 IRD	 label.	 First,	
since	2014,	all	 IRDs	undergo	nucleic	acid	 testing	 (NAT)	 for	HIV	and	
hepatitis C. This shortens the window period from 2- 3 months (for 
HCV)	to	less	than	2	weeks,	reducing	the	risk	of	window	period	infec-
tion	 compared	 to	 antibody	 screening	 alone	by	 as	much	at	10-	fold.4 
Second,	 curative	HCV	 treatments	 are	 now	available	 and	 the	 conse-
quence	of	HCV	transmission	is	less	significant	than	other	risks	associ-





the	 true	 risk	associated	with	 IRD,	and,	 just	as	 importantly,	 the	 risks	
associated	with	declining	an	IRD	organ	offer.
Into	 this	 the	 rapidly	 evolving	 situation,	 the	 current	 report	 by	
Bowring	et	al.	is	most	welcome.	Using	2010-	2014	Scientific	Registry	
of	 Transplant	 Recipients	 data,	 the	 investigators	 identified	 104,998	
potential	 recipients	 offered	 an	 IRD	 kidney	 and	 compared	outcomes	






offer	 realized	a	 significant	 survival	 benefit,	with	 a	48%	 reduction	 in	
risk	of	death	6	months	post	decision.	Crude	mortality	at	5	years	was	
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